Epoietin Use in Older Adults with Anemia

Primary Recommendation

The American Society of Clinical Oncology recommends initiating epoietin in older adults with chemotherapy-associated anemia when hemoglobin falls below 10 g/dL to reduce transfusion requirements, but exercise heightened caution due to increased thromboembolic risk in this population 1, 2, 3

A comprehensive workup is required to exclude reversible causes of anemia before initiating epoietin in any older adult, including a thorough drug exposure history to identify medications causing bone marrow suppression, peripheral blood smear review, iron, folate, and vitamin B12 deficiency testing, reticulocyte count, occult blood loss assessment, and renal function evaluation 1, 4, 5
The American Society of Hematology recommends Coombs' testing for patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, or autoimmune disease history 1, 5
Endogenous erythropoietin levels should be evaluated in myelodysplastic syndrome patients before initiating epoietin therapy 1, 6

Epoietin is recommended as a treatment option when hemoglobin has decreased to less than 10 g/dL in patients receiving chemotherapy, with RBC transfusion remaining an alternative depending on clinical severity 1, 3, 5
For older adults with hemoglobin between 10-12 g/dL, the decision to initiate epoietin requires individualized clinical judgment weighing specific risk factors, including limited cardiopulmonary reserve, coronary artery disease, symptomatic angina, or substantially reduced exercise capacity 1, 2, 3

Older adults face significantly elevated thromboembolic risk with epoietin therapy, requiring careful risk-benefit assessment, particularly in those with previous thrombosis history, recent surgery, prolonged immobilization or limited activity, or multiple myeloma patients on thalidomide/lenalidomide with doxorubicin or corticosteroids 1, 2, 3
Epoietin therapy has been associated with increased mortality risk and shorter survival in cancer patients, particularly those receiving curative-intent chemotherapy, and should be minimized in patients with malignancy being treated with curative intent 1, 4, 5, 7

The FDA-approved starting doses for epoietin alfa are 150 U/kg three times weekly or 40,000 U weekly subcutaneously, and for darbepoetin alfa are 2.25 μg/kg weekly or 500 μg every 3 weeks subcutaneously 4
Both epoetin alfa and darbepoetin alfa are considered equivalent in effectiveness and safety 1, 2, 3, 5

Epoietin should be avoided in older adults with cancer not receiving concurrent chemotherapy, except in lower-risk myelodysplastic syndromes 7
The FDA label limits the indication for epoietin to patients receiving chemotherapy for palliative intent, though clinical judgment is required as no studies have evaluated outcomes by chemotherapy intent 1, 4, 5

The American Society of Hematology recommends assessing iron stores, including serum ferritin, transferrin saturation, and TIBC, to exclude iron deficiency before initiating Recormon, as iron deficiency will blunt response 8, 9
Evaluating renal function is crucial, as renal insufficiency affects both anemia and ESA dosing, according to the National Kidney Foundation 8

The American Society of Clinical Oncology recommends considering RBC transfusion as the primary intervention for severe anemia, given the severity of anemia and clinical circumstances, with a hemoglobin threshold of 10 g/dL 8, 10
Epoetin can be initiated concurrently with or following transfusion to prevent future transfusion requirements, as suggested by the European Society for Medical Oncology 8

The primary regimen for Recormon is 150 U/kg subcutaneously three times weekly for a minimum of 4 weeks, with monitoring of hemoglobin weekly during initiation, as recommended by the American College of Physicians 8, 9, 11
An alternative weekly regimen of 40,000 U subcutaneously once weekly may be considered, although it is based on weaker evidence, according to the Journal of Clinical Oncology 12

The target hemoglobin range is 10-12 g/dL, with dose titration to maintain hemoglobin near 12 g/dL, as recommended by the National Comprehensive Cancer Network 8, 9
Reducing the dose by 25% if hemoglobin increases >1 g/dL in any 2-week period is suggested, to avoid exceeding the target hemoglobin, according to the European Society for Medical Oncology 8, 9

Considering intravenous iron supplementation to enhance response is recommended, with IV iron significantly improving hemoglobin response compared to oral iron or no iron in lymphoma patients, as suggested by the American Society of Hematology 12
Monitoring iron parameters, including ferritin and transferrin saturation, periodically is crucial, although optimal timing is not established, according to the National Kidney Foundation 9